Dublin, July 30, 2024 (GLOBE NEWSWIRE) -- The "Lewy Body Disease - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.
This "Lewy Body Disease - Pipeline Insight, 2024" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Lewy Body Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
"Lewy Body Disease- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lewy Body Disease pipeline landscape is provided which includes the disease overview and Lewy Body Disease treatment guidelines.
The assessment part of the report embraces, in depth Lewy Body Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lewy Body Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Lewy Body Disease R&D. The therapies under development are focused on novel approaches to treat/improve Lewy Body Disease.
Lewy Body Disease Emerging Drugs Chapters
This segment of the Lewy Body Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Lewy Body Disease Emerging Drugs
LY3154207: Eli Lilly and Company
Mevidalen (LY3154207) is a selective and orally active D1-positive allosteric modulator with >1000-fold selectivity for the human D1 receptor over other tested targets. Mevidalen increases the extracellular level of acetylcholine in the prefrontal cortex and enhances the affinity of dopamine for the D1 receptor. This amplifies the responses to endogenous and exogenous dopamine, which may improve motor and cognitive symptoms of Parkinson Disease and Lewy body dementias as well as sleepiness, mood, and apathy. Currently, the drug is in Phase II stage of its clinical trial evaluation for the treatment of Lewy Body Disease.
Neflamapimod: CervoMed, Inc.
Neflamapimod is an investigational drug that is a brain-penetrant, oral small molecule that inhibits the intra-cellular enzyme p38 MAP kinase alpha (p38?). P38?, which is expressed in neurons under conditions of stress and disease, plays a major role in inflammation-induced synaptic toxicity, leading to impairment of synaptic function. Neflamapimod targets and inhibits p38 alpha, a cellular enzyme linked to the in?ammation and synaptic dysfunction that cause neurological disease progression. Currently, the drug is in Phase II stage of its clinical trial evaluation for the treatment of Lewy body disease.
UB 312: Vaxxinity
UB 312 targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's and other synucleinopathies, such as dementia with Lewy Body ("DLB") and multiple system atrophy ("MSA"). The first part of a Phase I trial in healthy volunteers has shown UB-312 to be well tolerated, with no significant safety findings, and immunogenic, with a high responder rate and antibodies that cross the blood-brain barrier ("BBB"). Currently, the drug is in Phase I stage of its development for the treatment of Lewy body disease.
Major Players in Lewy Body Disease
There are approx. 10+ key companies which are developing the therapies for Lewy Body Disease. The companies which have their Lewy Body Disease drug candidates in the most advanced stage, i.e. Phase III include, Eli Lilly and Company and CervoMed, Inc.
Lewy Body Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Lewy Body Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lewy Body Disease drugs.
Key Questions
- How many companies are developing Lewy Body Disease drugs?
- How many Lewy Body Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lewy Body Disease?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Lewy Body Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Lewy Body Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Annovis Bio
- CervoMed, Inc
- Vaxxinity
- Eisai Inc.
- Cognition Therapeutics
- Eli Lilly and Company
- Athira Pharma
- NLS Pharmaceutics
Key Products
- Buntanetap
- Neflamapimod
- UB 312
- E2027
- CT1812
- LY3154207
- ATH-1017
- Oxafuramine
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Lewy Body Disease Report Insights
- Lewy Body Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Lewy Body Disease Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/cl016j
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
